SLC5A2 and type 2 diabetes mellitus: Chilton suggested that the overall cardio- and reno-protective effects of SGLT2 inhibitors in T2D patients with high CV risk are most likely attributable to multiple mechanisms, including hemodynamic, metabolic, anti-inflammatory, and renal effects [80].